What is the rationale for erythropoietin therapy in chronic kidney disease?

What is the rationale for erythropoietin therapy in chronic kidney disease?

• A. To treat the associated anemia
• B. To control hypertension
• C. To correct the acid-base balance
• D. To increase perfusion in the kidney

Answer: (A)

In chronic kidney disease, the damaged kidneys produce less erythropoietin, the hormone that signals the bone marrow to make red blood cells. Erythropoietin therapy provides this signal or a similar agent to stimulate red blood cell production, correcting the anemia that often accompanies CKD. By increasing the number of circulating red blood cells, the blood’s oxygen-carrying capacity improves, which helps reduce fatigue, shortness of breath, and exercise intolerance and lowers the need for blood transfusions. This is why the rationale centers on treating the associated anemia rather than addressing blood pressure, acid-base balance, or kidney perfusion. A few important notes: the anemia response depends on adequate iron stores, so iron status is assessed and corrected as needed before or during therapy. Treatment requires careful monitoring of hemoglobin to avoid rising too quickly or reaching very high levels, since that can increase cardiovascular risk. Additionally, some patients may experience hypertension or thrombotic events as potential side effects, so ongoing monitoring is essential.

In chronic kidney disease, the damaged kidneys produce less erythropoietin, the hormone that signals the bone marrow to make red blood cells. Erythropoietin therapy provides this signal or a similar agent to stimulate red blood cell production, correcting the anemia that often accompanies CKD. By increasing the number of circulating red blood cells, the blood’s oxygen-carrying capacity improves, which helps reduce fatigue, shortness of breath, and exercise intolerance and lowers the need for blood transfusions. This is why the rationale centers on treating the associated anemia rather than addressing blood pressure, acid-base balance, or kidney perfusion.

A few important notes: the anemia response depends on adequate iron stores, so iron status is assessed and corrected as needed before or during therapy. Treatment requires careful monitoring of hemoglobin to avoid rising too quickly or reaching very high levels, since that can increase cardiovascular risk. Additionally, some patients may experience hypertension or thrombotic events as potential side effects, so ongoing monitoring is essential.